Piper Jaffray reiterated its Overweight rating on MAKO Surgical MAKO and lowered the price target from $28.00 to $23.00.
Piper Jaffray said, “Our revised estimates and price target should position the stock to perform, in the wake of what has been a very volatile 12-month period for MAKO. While our new estimates and target are reduced (robot sales up 14%, implant sales up 40%, total
revenues up 30%, $23 down from $28), the numbers strike a compelling growth profile by any standard and we believe there remains potential for upside revisions. MAKO clearly remains a “show-me” stock, and management must position 2013 outlook balancing growth and conservatism, and importantly, meeting or beating numbers for a quarter or two.”
MAKO Surgical closed at $12.22 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in